Theranexus colloborates with AI expert Dyliss

The goal of the R&D partnership is to gain insights into the regulation of neurons and glial cells and to make use of artificial intelligence to select new therapeutics assets. The collaboration complements the company's plans to develop a new Neurolead platform.

“This new collaboration emphasizes our commitment to extending and systematizing the concept of therapeutic targeting of neuroglial interactions to address the significant and compelling needs of patients, a concept for which we aim to play a leading role,” stated Mathieu Charvériat, Chief Scientific Officer for Theranexus.

Dyliss focuses on identifiction of complex signatures for pathologies. Euronext-listed Theranexus develops drug candidates for the treatment of nervous system diseases. Theranexus identified the key role of glial cells in the body’s response to psychotropic drugs that target neurons. The company wants to improve the efficacy of approved psychotropic drugs by combining them with a glial cell modulator. This strategy of combining its innovations with registered drugs means Theranexus can significantly reduce development time and costs and considerably increase the chance of its drugs reaching the market.